Additionally, because BC tumours are very heterogeneous, a tissue biopsy is mandatory to obtain the molecular classification of each tumour, that is based on the expression of several biomarkers, such as estrogen receptor (ER), progesterone receptor (PR), HER2 (human epidermal growth factor receptor 2) overexpression, or Ki-67, which determine the treatment choice [4,6,7]. The gene discussed is ERBB2; the disease is breast cancer.